Sangui BioTech International Inc.: Increase in sales in the first quarter of 121% - Highest quarterly sales in the company's history

Issuer: Sangui BioTech International Inc. / Key word(s): Development of Sales Sangui BioTech International Inc.: Increase in sales in the first quarter of 121% - Highest quarterly sales in the company's history 12.10.2022 / 12:57 CET/CEST The issuer is solely responsible for the content of this announcement. Sangui BioTech: Increase in sales in the first quarter of 121% Highest quarterly sales in the company's history   Hamburg, October 12, 2022: According to preliminary and unaudited numbers, the Sangui Biotech International Inc. was able to increase its license revenue from the wound spray Granulox in the first quarter of its fiscal year 2023 (01.07.2022 to 30.06.2023) by USD 22,469 or 121% to USD 41,029. Considering the effects from the exchange rate development of the US dollar to the Euro, the increase in license revenue is even 159%. In the first quarter of the 2023 financial year, the highest license revenues have been achieved since the license agreement was concluded. The reason for the increase in license revenue is, among other things, the mandatory reimbursement of the costs for the wound spray by health insurance in the Netherlands and in the Czech Republic. Against the background of this development and the current level of the US dollar exchange rate, Sangui expects to increase sales of at least 30% in the first half of its financial year.     Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. For more information please contact: Sangui Biotech International, Inc. Thomas Striepe e-mail: [e-mail] Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.   Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com